Benadryl Does Not Lower ANC
Benadryl (diphenhydramine) does not lower the absolute neutrophil count (ANC). There is no evidence in the FDA drug labeling or medical literature that diphenhydramine causes neutropenia or reduces ANC 1.
Key Evidence
The FDA-approved Benadryl labeling contains no warnings about neutropenia, bone marrow suppression, or effects on white blood cell counts 1. The warnings focus on anticholinergic effects (glaucoma, urinary retention, breathing problems), sedation, and drug interactions—but make no mention of hematologic toxicity.
Historical Context
One older animal study from 1975 showed that diphenhydramine could inhibit bone marrow reactions (decreased nucleated cell counts) caused by bacterial endotoxin in mice 2. However, this was a protective effect against endotoxin-induced changes, not a direct neutropenia-causing mechanism. This finding has no clinical relevance to human neutropenia risk.
Clinical Implications
Diphenhydramine is safe to use in patients with low ANC. It does not require dose adjustment or avoidance in neutropenic patients.
If a patient on Benadryl develops neutropenia, look for other causes: chemotherapy agents, antithyroid drugs (carbimazole, thiamazole), clozapine, carbamazepine, or underlying bone marrow disorders 3, 4, 5.
The extensive guidelines on neutropenia management in cancer patients, clozapine therapy, and other conditions never list antihistamines as causative agents 6, 7, 8, 5.
Common Pitfall
Do not confuse diphenhydramine with drugs that genuinely cause neutropenia. Medications requiring ANC monitoring include clozapine (monitor weekly for 18 weeks, then monthly) 5, antithyroid drugs (check if ANC <1000/mm³) 3, and chemotherapy agents 6.